Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Migraine

24 Jan 05

For people with migraine, today’s world is a better world than the one their parents knew. The last 15 years have seen major advances, giving us not only a much clearer understanding of the disorder but also considerably more effective therapies. Treatments exist that – if made available and used in the right way – can substantially relieve the majority of people affected by migraine.
CSF Medical

High Incidence of surgical site infections in Europe presents a risk to patients, and an economic burden

21 Jan 05

The increasing incidence of surgical site infections (SSIs) among hospital patients in Europe has led to a call to action for cost-effective preventative measures to be put in place by hospitals, to help minimize the risk of infection and the cost impact on healthcare systems. A consensus paper, developed by a number of leading healthcare experts in Europe and published today in the International Wound Journal, indicates the scale of the problem and the estimated financial impact on the health
Wound Healing Research Unit

INC RESEARCH MOVES INTO NEW EUROPEAN HEADQUARTERS

20 Jan 05

INC RESEARCH MOVES INTO NEW EUROPEAN HEADQUARTERS TO ACCOMMODATE CONTINUING GLOBAL EXPANSION
Kevan Nicholson

Epilepsy

17 Jan 05

Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications

siRNA Strategies

17 Jan 05

Knowledge will be pooled and ideas investigated through focused discussion topics: * What approach to take to target validation? * Establishing the true impact of off-target effects * Unravelling the different pathways * What can delivery systems achieve? * What are the pros and cons of different chemical modification? * Addressing pharmacokinetics and modification issues for each disease What do I need for clinical testing of an siRNA compound?
Charlotte Hayes

Addressing the unmet need of diabetics with new generation non-insulin antidiabetics

17 Jan 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
LeadDiscovery

Morgan Levy (formally E-Focus Resourcing) has rebranded.

13 Jan 05

Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL

SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

04 Jan 05

The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
LeadDiscovery

Sorafenib offers hope in the battle for liver cancer survival

20 Dec 04

The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
Datamonitor

Fulfilling a Millennium Healthcare Promise

15 Dec 04

Despite the advances made in healthcare there remains a startling amount of the world’s population that is unable to gain access to even the most basic services and treatments. This is an issue that has attracted considerable media coverage and represents a challenge for all those involved in healthcare to overcome.
Dr Faiz Kermani

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.